José A. Covarrubias-Cobos

Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond

D. Gladman, V. Strand, J. Cappelleri, 2019, RMD Open.

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs

D. Gladman, V. Strand, J. Cappelleri, 2019, RMD Open.